Unlocking the Future of Dementia Science: Discover our Topics for the AAIC 2023

Discover cutting-edge dementia science at AAIC Amsterdam. Breakthroughs and connections thrive as leading experts unite at the world's largest conference on Alzheimer's research.

At the Alzheimer’s Association International Conference (AAIC) in Amsterdam, our brilliant science team showcased our groundbreaking theories and revolutionary breakthroughs. They eagerly engaged with distinguished experts, including leading basic scientists, clinical researchers, early career investigators, clinicians, and the esteemed care research community. This gathering was no ordinary conference; it was the world’s largest and most influential platform dedicated to dementia science. Join us in this vibrant hub of innovation and collaboration, where ideas flourish and connections abound.

Blood Pressure

A Phase I trial suggests that IGC-AD1 may not contribute to increased risk in AD associated with BP and BPV

Reduction of NPI

Reduction of NPI

An oral combination of low doses of tetrahydrocannabinol (THC) and melatonin (IGC-AD1) administered…

AAIC 2023

Agitation

IGC AD1, an oral solution combining low doses of Tetrahydrocannabinol (THC) and melatonin…

Suicide

Suicide

Low doses of THC + melatonin (IGC-AD1) did not increase the risk of developing suicidal ideation nor behavior…

Apathy

Apathy

IGC-AD1, a tetrahydrocannabinol (THC) and melatonin combination, has the potential to treat Apathy in Alzheimer’s disease.

Genotyping

Genotyping

Polymorphism of CYP2c9 in Alzheimer’s affects drug metabolism and should be considered as a part of dosing…

Recent Post

Follow Us

Related Posts

Insights into-new alzheimers treatments

Posted on: September 13, 2023 in Blogs | Life Science Podcast | Life Science BlogsBy: Ayesha Rashid, PhDThis episode features an interview with Ram Mukunda and Claudia Grimaldi from IGC Pharma, a clinical-stage pharmaceutical company focused on improving the

Read More »